Ruth Frampton, Samantha Hocking, Jennifer R Snaith, Jerry R Greenfield
{"title":"Targeting cardiometabolic risk in type 1 diabetes through incretin physiology.","authors":"Ruth Frampton, Samantha Hocking, Jennifer R Snaith, Jerry R Greenfield","doi":"10.1016/j.tem.2025.06.004","DOIUrl":null,"url":null,"abstract":"<p><p>People living with type 1 diabetes have significantly increased cardiovascular risk compared with the general population. Traditional risk factors include hypertension, dyslipidaemia, and obesity. However, those with type 1 diabetes contend with treatment-induced insulin resistance and pancreatic and incretin hormone dysfunction, leading to dysglycaemia, which also impacts cardiovascular risk. Here, we highlight the underlying metabolic environment in type 1 diabetes with a focus on glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon physiology. With the emergence of incretin-based therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a combined GLP-1/GIP receptor agonist) targeting these receptor pathways, there is now potential to directly target metabolic deficits to address cardiometabolic risk in a type 1 diabetes population.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tem.2025.06.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
People living with type 1 diabetes have significantly increased cardiovascular risk compared with the general population. Traditional risk factors include hypertension, dyslipidaemia, and obesity. However, those with type 1 diabetes contend with treatment-induced insulin resistance and pancreatic and incretin hormone dysfunction, leading to dysglycaemia, which also impacts cardiovascular risk. Here, we highlight the underlying metabolic environment in type 1 diabetes with a focus on glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon physiology. With the emergence of incretin-based therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a combined GLP-1/GIP receptor agonist) targeting these receptor pathways, there is now potential to directly target metabolic deficits to address cardiometabolic risk in a type 1 diabetes population.
期刊介绍：
Trends in Endocrinology and Metabolism (TEM) stands as a premier Reviews journal in the realms of metabolism and endocrinology. Our commitment is reflected in the publication of refined, concise, and highly impactful articles that delve into cutting-edge topics, encompassing basic, translational, and clinical aspects. From state-of-the-art treatments for endocrine diseases to groundbreaking developments in molecular biology, TEM provides comprehensive coverage.
Explore recent advancements in diabetes, endocrine diseases, obesity, neuroendocrinology, immunometabolism, molecular and cellular biology, and a myriad of other areas through our journal.
TEM serves as an invaluable resource for researchers, clinicians, lecturers, teachers, and students. Each monthly issue is anchored by Reviews and Opinion articles, with Reviews meticulously chronicling recent and significant developments, often contributed by leading researchers in specific fields. Opinion articles foster debate and hypotheses. Our shorter pieces include Science & Society, shedding light on issues at the intersection of science, society, and policy; Spotlights, which focus on exciting recent developments in the literature, and single-point hypotheses as Forum articles. We wholeheartedly welcome and encourage responses to previously published TEM content in the form of Letters.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
